Organization and Summary of Significant Accounting Policies (Tables) - Titan Pharmaceuticals Inc [Member]

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Schedule of Activity related to Accounts Receivable

The following table presents the activity related to our accounts receivable for the years ended December 31, 2024 and 2023.

(In thousands of U.S. dollars)
Balance as of January 1, 2023	$	36
Additions		184
Deductions		(174	)
Balance as of December 31, 2023	$	46
Additions		-
Deductions		(46	)
Balance as of December 31, 2024	$	-

Schedule of anti-dilutive effect

The table below presents common shares underlying stock options and warrants that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect:

	Three Months Ended
	March 31,
(in thousands)	2025		2024
Weighted-average anti-dilutive common shares resulting from options		80		93
Weighted-average anti-dilutive common shares resulting from convertible note		-		15
Weighted-average anti-dilutive common shares resulting from convertible preferred		1,019		332
Weighted-average anti-dilutive common shares resulting from warrants		468		476
		1,567		916

	December 31,
	2024		2023
Weighted-average anti-dilutive common shares resulting from convertible preferred stock		593		-
Weighted-average anti-dilutive common shares resulting from convertible notes		7		-
Weighted-average anti-dilutive common shares resulting from stock options and awards		92		70
Weighted-average anti-dilutive common shares resulting from warrants		477		427
		1,169		497